Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Table 4.

Randomized phase III trials of interferon-α with or without bevacizumab in advanced renal cell cancer patients not having prior systemic therapy [Rini et al. 2008c; Escudier et al. 2007c].

Treatment PFS p value OS p value
AVOREN Study
Interferon-α  + bevacizumab 10.2 0.0001 NR NA
Interferon-α 5.4 19.8
CALGB 90206
Interferon-α  + bevacizumab 8.5 0.0001 NR NA
Interferon-α 5.2 NR

NR, not reached; OS, overall survival; PFS, progression-free survival.